Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
  • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/775—Apolipopeptides

Definitions

• the current invention is in the field of lipoproteins and lipid particles. It is reported herein a method for producing a lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, as well as a tetranectin-apolipoprotein A-I.
• Plasma lipoproteins are soluble protein-lipid complexes that carry out lipid transport and metabolism in blood.
• Several major classes of lipoproteins are distinguished on the basis of their density, size, chemical compositions, and functions.
• high-density-lipoprotein (HDL) particles alternatively denoted as high-density-lipid particles, are made up of several subclasses that vary in their average molecular weight of from 180 kDa to 360 kDa. Their average lipid and protein content is 50 % by weight of each.
• Phosphatidylcholine (PC) accounts for 38 % of the total lipid followed by cholesteryl esters and small amounts of other polar and non-polar lipids, including free cholesterol.
• the main protein component is apolipoprotein A-I (Apo A-I), representing about 60 % of total protein weight in human HDL.
• LDL low density lipoprotein
• HDL high density lipoprotein
• Cholesterol taken up by HDL particles is esterified by the enzyme lecithin-cholesterol-acyl-transferase (LCAT).
• LCAT lecithin-cholesterol-acyl-transferase
• the cholesterol ester has an increased hydrophobicity and diffuses towards the core of the HDL particle.
• the HDL-cholesterol-ester particle may be delivered to the liver and removed from circulation.
• HDL particles and its major polypeptide apolipoprotein A-I participate in the reverse cholesterol transport (RCT).
• RCT reverse cholesterol transport
• the apolipoprotein A-I increases the efflux of cholesterol from cells, e.g. from cells of the wall of blood vessels, the binding of the lipid and the activation of the lecithin-cholesterol-acetyl-transferase and thereby the elimination of cholesterol via plasmatic flow by the liver.
• This is an active transport process involving the cell membrane protein ATP-binding- cassette-transporter-A-I (ABCA-I).
• Apolipoprotein A-I and apolipoprotein-based therapeutics were already identified in the late 70ties and early 80ties of the last century.
• apolipoprotein A-I-Milano containing lipid particles were already identified in the late 70ties and early 80ties of the last century.
• Apolipoprotein A-I-Milano a dimeric form of wild-type apolipoprotein A-I, was designed according to a naturally occurring mutant of the apolipoprotein A-I molecule. The dimer formation is enabled by the exchange of amino acid residue 173 (arginine) by cysteine allowing the formation of a disulfide bond.
• nanostructures suitable for sequestering cholesterol and other molecules comprising a core comprising an inorganic material are reported.
• Methods for producing nanoscale bound bilayers comprising the depletion of detergents from intermediate mixtures within about one hour of obtaining the mixture are reported in WO 2009/097587.
• pharmaceutical compositions for treating or preventing coronary artery disease are reported.
• WO 2005/084642 an apoprotein-cochelate composition is reported.
• WO 2007/137400 a method and compound for the treatment of valvular stenosis is reported.
• Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes are reported in WO 2005/041866.
• lipid particles can be formed starting from a solution comprising the denatured protein by rapid dilution into a solution comprising at least one lipid and a detergent. In this step the concentration of the detergent is reduced below the CMC. With this method a preceding naturation step can be omitted and, thus, with the method as reported herein a faster production of lipid particles is possible.
• the dilution is about 1 :3 (v:v) to about 1 :20 (v:v). In one embodiment the dilution is about 1 :5 (v:v) to about 1 : 10 (v:v). In one embodiment the dilution is about 1 :5 (v:v).
• the detergent is diluted at at least a factor of about 3. In one embodiment the detergent is diluted at at least a factor of about 5.
• One aspect as reported herein is a method for producing a lipid particle comprising the following steps: i) providing a first solution comprising denatured protein,
• ii) adding the first solution to a second solution comprising at least one lipid and a detergent but which does not comprise the protein, and iii) removing the detergent from the solution obtained in step ii) and thereby producing a lipid particle.
• the first solution is free of lipids.
• the protein is a recombinantly produced protein.
• the protein is an apolipoprotein. In another embodiment the apolipoprotein is a purified apolipoprotein.
• the apolipoprotein has the amino acid sequence selected from the amino acid sequences of SEQ ID NO: 01, 02, and 04 to 52, and 66 to 67 or comprises at least a contiguous fragment comprising at least 80 % of the amino acid sequence of SEQ ID NO: 01, 02, and 04 to 52, and 66 and 67. In one embodiment the apolipoprotein has an amino acid sequence or is at least a contiguous fragment of at least 80 % of an amino acid sequence selected from SEQ ID NO: 01, 02, and 04 to 52, and 66 and 67.
• the apolipoprotein is an apolipoprotein A-I. In one embodiment the apolipoprotein A-I is human apolipoprotein A-I. In a further embodiment the apolipoprotein is a tetranectin-apolipoprotein A-I that has the amino acid sequence of SEQ ID NO: 01, or SEQ ID NO: 02, or SEQ ID NO: 66, or SEQ ID NO: 67.
• the apolipoprotein has the amino acid sequence of SEQ ID NO: 06 with a mutation selected from R151C and R197C.
• the second solution has a volume that is at least two-times the volume of the first solution.
• the second solution has about 3 -times to about 20-times the volume of the first solution. In one embodiment the second solution has about 5-times to about 10-times the volume of the first solution. In one embodiment the at least one lipid is selected from phospholipids, fatty acids and steroid lipids.
• the at least one lipid is at least two lipids, optionally selected independently of each other from phospholipids, fatty acids and steroid lipids. In another embodiment the at least one lipid is of from one to four lipids, i.e. it is selected from the group comprising one lipid, two lipids, three lipids, and four lipids.
• the second solution comprises a phospholipid, a lipid, and a detergent.
• the second solution is consisting of a phospholipid, a lipid, a detergent and a buffer salt.
• the lipids are two different phospholipids. In another embodiment the lipids are two different phosphatidylcholines. In another embodiment the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the first phosphatidylcholine is POPC and the second phosphatidylcholine is DPPC.
• the detergent is selected from sugar-based detergents, polyoxyalkylene-based detergents, bile-salt based detergents, synthetic detergents or a combination thereof. In another embodiment the detergent is selected from cholic acid, Zwittergent or a salt thereof.
• the first solution is substantially free of lipid particles.
• the method comprises after step ii) and prior to step iii) the following step iia) incubating the solution obtained in step ii). In one embodiment the incubating and/or removing is at a temperature of from 4 °C to 45 °C.
• polypeptide is incubated with the detergent for about 0.5 hours to about 60 hours. In one embodiment the polypeptide is incubated with the detergent for about 0.5 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 2 hours to about 60 hours. In one embodiment the polypeptide is incubated with the detergent for about 12 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 16 hours.
• the detergent is a detergent with a high CMC. In another embodiment the detergent is a detergent with a CMC of at least 5 mM. In another embodiment the detergent is a detergent with a CMC of at least 10 mM.
• the concentration of the detergent is at least 0.5 x CMC in the second solution.
• the removing is by diafiltration or dialysis or adsorption.
• the adsorption is in one embodiment selected from affinity or hydrophobic chromatography.
• the removing is by dialysis.
• the first solution has a first volume
• the second solution has a second volume
• the protein in the first solution has a defined concentration
• the lipids and the detergent in the second solution each have a defined concentration
• the concentration of the apolipoprotein, of the lipids and of the detergent is changed/reduced allowing the formation of a lipid particle.
• the method comprises the following step: iv) purifying the lipid particle and thereby producing a lipid particle.
• One aspect as reported herein is a lipid particle obtained by a method as reported herein.
• One aspect as reported herein is a pharmaceutical composition comprising a lipid particle comprising apolipoprotein obtained with a method as reported herein as well as the use of a lipid particle as reported herein for the manufacture of a medicament for the treatment of arteriosclerosis.
• apolipoprotein denotes a protein that is comprised in a lipid or lipoprotein particle, respectively.
• Apolipoprotein A-I denotes an amphiphilic, helical polypeptide with protein-lipid and protein-protein interaction properties.
• Apolipoprotein A-I is synthesized by the liver and small intestine as prepro-apolipoprotein of 267 amino acid residues which is secreted as a pro-apolipoprotein that is cleaved to the mature polypeptide having 243 amino acid residues.
• Apolipoprotein A-I is consisting of 6 to 8 different amino acid repeats consisting each of 22 amino acid residues separated by a linker moiety which is often proline, and in some cases consists of a stretch made up of several residues.
• human apolipoprotein A-I SEQ ID NO: 06
• naturally occurring variants exist, such as P27H, P27R, P28R, R34L, G50R, L84R, D113E, A-A119D, D127N, deletion of K131, K131M, W132R, E133K, R151C (amino acid residue 151 is changed from Arg to Cys, apolipoprotein A-I-Paris), E160K, E163G, P167R, L168R, E171V, P189R, R197C (amino acid residue 173 is change from Arg to Cys, apolipoprotein A-I-Milano) and E222K.
• the tetranectin-apolipoprotein A-I comprises a fragment of the cleavage site of Immunoglobulin A protease (IgA protease).
• IgA protease Immunoglobulin A protease
• the recognition sites known from IgA proteases comprise the following sequences with " ⁇ " denoting the position of the cleaved bond:
• Pro-Pro ⁇ Ser-Pro (SEQ ID NO: 62) Pro-Pro ⁇ Ala-Pro (SEQ ID NO: 63) Pro-Pro ⁇ Thr-Pro (SEQ ID NO: 64) Pro-Pro ⁇ Gly-Pro (SEQ ID NO: 65), wherein the first three are more frequently chosen and cleaved.
• the term “forceapolipoprotein mimic” denotes a synthetic polypeptide that mimics the function of the respective apolipoprotein.
• an equipapolipoprotein A-I mimic is a synthetic polypeptide that shows comparable biological function with respect to removal of cholesterol, i.e. reverse cholesterol efflux, as the natural apolipoprotein A-I.
• the apolipoprotein A-I mimic comprises at least one amphiphilic alpha-helix with positively charged amino acid residues clustered at a hydrophobic-hydrophilic interface and negatively-charged amino acid residues clustered at a center of a hydrophilic face.
• the apolipoprotein mimic comprise a repeat polypeptide of from 15 to 29 amino acid residues, in one embodiment of 22 amino acid residues (PVLDEFREKL EELEALKQKLK (SEQ ID NO: 04); PVLDLFRELLNELLEAL KQKLK (SEQ ID NO: 05)).
• At least one denotes one, two, three, four, five, six, seven, eight, nine, ten or more.
• at least two denotes two, three, four, five, six, seven, eight, nine, ten or more.
• the term “humancardiovascular disease” in general denotes a disease or condition with respect to heart or blood vessels, such as arteriosclerosis, coronary heart disease, cerebrovascular disease, aortoiliac disease, ischemic heart disease or peripheral vascular disease.
• a disease may not be discovered prior to an adverse event as a result of the disease, such as myocardial infarct, stroke, angina pectoris, transient ischemic attacks, congestive heart failure, aortic aneurysm, mostly resulting in death of the subject.
• cholate denotes 3a,7a,12a-trihydroxy-5P-cholan-24-oic acid or a salt thereof, especially the sodium salt.
• the formation of lipid particles may be performed by incubating the apolipoprotein with detergent solubilized lipids at their respective transition temperature.
• critical micelle concentration and its abbreviation “CMC”, which can be used interchangeably, denote the concentration of surfactants or detergents above which individual detergent molecules (monomers) aggregate spontaneously to micelles (micelles, round rods, lamellar structures etc.).
• conservative amino acid modification denotes modifications of the amino acid sequence which do not affect or alter the characteristics of the lipid particle or the apolipoprotein according to the invention.
• Modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
• Conservative amino acid modifications include ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g. lysine, arginine, histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g.
• basic side chains e.g. lysine, arginine, histidine
• acidic side chains e.g. aspartic acid, glutamic acid
• uncharged polar side chains e.g. glycine, asparagine, glutamine
• a “variant” protein refers therefore herein to a molecule which differs in amino acid sequence from a "parent" protein's amino acid sequence by up to ten, in one embodiment from about two to about five, additions, deletions, and/or substitutions Amino acid sequence modifications can be performed by mutagenesis based on molecular modeling as described by Riechmann, L., et al., Nature 332 (1988) 323- 327, and Queen, C, et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033.
• the term “detergent” denotes a surface active chemical substance.
• a “detergent” is generally an amphiphatic molecule with a non-polar, hydrophobic part and a polar, hydrophilic part.
• the term “zwitterionic detergent” denotes a surface active chemical compound that has overall zero charge and at the same time comprises at least one positively charged moiety and at least one negatively charged moiety.
• the detergent is selected from sugar-based detergents, polyoxyalkylene-based detergents, bile-salt based detergents, synthetic detergents or a combination thereof.
• the term solubility-based detergent denotes a detergent selected from n-octyl-beta-D-glucopyranoside, n-nonyl-beta-D-glucopyranoside, n- dodecyl-beta-D-maltopyranoside, or 5-cyclohexylpentyl-beta-D-maltopyranoside, and derivatives thereof.
• the term corpus-salt based detergent denotes a detergent selected from sodium cholate, potassium cholate, lithium cholate, 3-[(3-chloramidopropyl) dimethylammonio]-yl-propane sulfonate (CHAPS), 3-[(3-chloramidopropyl) dimethylammonio]-2-hydroxyl propane sulfonate (CHAPSO), and derivatives thereof.
• the term FAQ polyoxyalkylene-based detergent denotes a detergent selected from Tween 20, Triton X-100, Pluronic F68, and a derivatives thereof.
• the term satisfyingsynthetic detergents denotes a detergent selected from Zwittergent 3-6, Zwittergent 3-8, Zwittergent 3-10, Zwittergent 3-12, and derivatives thereof.
• lipid-protein-complex comprising as main proteinaceous compound apolipoprotein A-I.
• immunoassay denotes standard solid-phase immunoassays with monoclonal antibodies involving the formation of a complex between an antibody adsorbed/immobilized on a solid phase (capture antibody), the antigen, and an antibody to another epitope of the antigen conjugated with an enzyme (tracer antibody).
• a sandwich is formed: solid phase-capture antibody-antigen-tracer antibody.
• the activity of the antibody-conjugated enzyme is proportional to the antigen concentration in the incubation medium.
• the standard sandwich method is also called double antigen bridging immunoassay because capture and tracer antibodies bind to different epitopes of the antigen.
• the immunoassays can be performed as homogeneous or heterogeneous immunoassay.
• the term "increase lipid efflux" and grammatical equivalents thereof denotes an increased level and/or rate of lipid efflux, promoting lipid efflux, enhancing lipid efflux, facilitating lipid efflux, upregulating lipid efflux, improving lipid efflux, and/or augmenting lipid efflux from cells or plaques.
• the lipid efflux comprises efflux of phospholipid, triglyceride, cholesterol, and/or cholesterol ester.
• the term denotes the phospholipid dimyristoyl phosphatidylcholine.
• the term “monomer” denotes the phospholipid l,2-di-palmitoyl-sn-glycero-3- phosphatidylcholine also referred to as 1,2-dipalmitoyl-phosphatidylcholine.
• multimer denotes a complex consisting of two or more monomers. A multimer is formed by non-covalent interactions between the monomers. Each monomer comprises a multimenzation domain. In one embodiment the multimer comprises 2 or 3 monomers. In another embodiment the multimerization domains interact via non-covalent interactions between the individual multimerization domains comprised in each monomer.
• multimerization domain denotes amino acid sequences capable of covalently or non-covalently associating two or more monomeric molecules.
• a multimerization domain is capable of interacting with multimerization domains of different, similar, or identical amino acid sequence.
• the multimerization domain is the tetranectin trimerising structural element or a derivative thereof that has an amino acid sequence that is at least 68 % identical with the consensus amino acid sequence of SEQ ID NO: 53.
• cysteine residue at position 50 of SEQ ID NO: 53 is substituted by a different amino acid residue, in another embodiment by a serine residue, or a threonine residue, or a methionine residue.
• Polypeptides comprising a multimerization domain can associate with one or more other polypeptides also comprising a multimerization domain.
• the multimer formation can be initiated simply by mixing the polypeptides under suitable conditions.
• the multimerization domain has the amino acid sequence of SEQ ID NO: 53 wherein of from 1 to 10 residues have been deleted from or added to the N- or C-terminus of the amino acid sequence.
• the multimerization domain has an amino acid sequence of SEQ ID NO: 53 wherein six or nine amino acid residues have been deleted from the N-terminus of the amino acid sequence.
• the multimerization domain has an amino acid sequence of SEQ ID NO: 53 wherein the N-terminal amino acid residue L or the N-terminal amino acid residues C and L have been deleted.
• the multimerization domain is the tetranectin trimerising structural element and has the amino acid sequence of SEQ ID NO: 54.
• the multimer is in one embodiment a homomer.
• the multimers may be homomers or heteromers, since different apolipoproteins comprising a multimerization domain can be combined to be incorporated into the multimer.
• the multimer is a trimeric homomer.
• the multimerization domain is obtained from tetranectin.
• the multimerization domain comprises the tetranectin trimerising structural element that has an amino acid sequence of SEQ
• the trimerising effect of the tetranectin trimerising structural element is caused by a coiled coil stmcture which interacts with the coiled coil structure of two other tetranectin trimerising structural elements to form a trimer.
• the tetranectin trimerising structural element may be obtained from human tetranectin, from rabbit tetranectin, from murine tetranectin, or from C-type lectin of shark cartilage.
• the tetranectin trimerising structural element comprises a sequence having at least 68 %, or at least 75 %, or at least 81 %, or at least 87 %, or at least 92 % identity with the consensus sequence of SEQ ID NO 53.
• non-covalent interactions denotes non-covalent binding forces such as ionic interaction forces (e.g. salt bridges), non-ionic interaction forces (e.g. hydrogen-bonds), or hydrophobic interaction forces (e.g. van-der-Waals forces or ⁇ -stacking interactions).
• ionic interaction forces e.g. salt bridges
• non-ionic interaction forces e.g. hydrogen-bonds
• hydrophobic interaction forces e.g. van-der-Waals forces or ⁇ -stacking interactions
• phase transition temperature denotes the temperature required to induce a change in the lipid physical state from the ordered gel phase, where the hydrocarbon chains are fully extended and closely packed, to the disordered liquid crystalline phase, where the hydrocarbon chains are randomly oriented and fluid.
• the formation of the lipid particles may be carried out at or above the phase transition temperature of the phospholipids / phospholipid mixtures used.
• the phase transition temperature of some phosphatidylcholines and mixtures thereof are listed in the following Table 1.
• Table 1 Transition temperatures of pure phosphatidylcholines and phosphatidylcholine mixtures.
• phosphatidylcholine denotes a molecule consisting of one glycerol moiety, two carboxylic acid moieties and one phosphocholine moiety, wherein the glycerol moiety is covalently bound to the other moieties each by a ester bond, i.e. two carboxylic ester bonds and one phosphoric ester bond, whereby the phosphoric ester bond is either to the 1-hydroxyl group or the 3-hydroxyl group of the glycerol moiety.
• ester bond i.e. two carboxylic ester bonds and one phosphoric ester bond, whereby the phosphoric ester bond is either to the 1-hydroxyl group or the 3-hydroxyl group of the glycerol moiety.
• carboxylic acid moiety denotes an organic moiety comprising at least one acyl group (R-C(O)O).
• the phosphatidylcholine may be of any kind or source.
• the phosphatidylcholine is selected from egg phosphatidylcholine, soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, distearoyl phosphatidylcholine, dilauryl phosphatidylcholine, dipalmitoyl phosphatidylcholine, l-myristoyl-2-palmitoyl phosphatidylcholine, l-palmitoyl-2- myristoyl phosphatidylcholine, l-palmitoyl-2-stearoyl phosphatidylcholine, 1- stearoyl-2-palmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, 1- palmitoyl-2-oleoyl phosphatidylcholine, l-oleoyl-2-palmitoyl phosphatidylcho
• All phospholipids as used herein may be derived from any source, i.e. (where appropriate) from soybean, milk, egg or even inner organs of animals excluding humans, they may be derived from natural origin, or semi-synthetic or even fully synthetic.
• polypeptide is a polymer consisting of amino acids joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 20 amino acid residues may be referred to as "peptides", whereas molecules consisting of two or more polypeptides or comprising one polypeptide of more than 100 amino acid residues may be referred to as "proteins".
• a polypeptide may also comprise non-amino acid components, such as carbohydrate groups, metal ions, or carboxylic acid esters. The non-amino acid components may be added by the cell, in which the polypeptide is expressed, and may vary with the type of cell. Polypeptides are defined herein in terms of their amino acid backbone structure or the nucleic acid encoding the same. Additions such as carbohydrate groups are generally not specified, but may be present nonetheless.
• the term “bestPOPC” denotes the phospholipid l-palmitoyl-2-oleoyl-sn-glycero-3- phosphatidylcholine also referred to as l-palmitoyl-2-oleoyl-phosphatidylcholine.
• the term "rapid” denotes a process that is completed within at most 10 hours. A rapid dilution is a process in which a first solution is added to a second solution in at most 10 hours. In one embodiment the process is completed in at most 5 hours, in a further embodiment in at most 2 hours.
• substantially free denotes that a solution comprising a protein an one or more lipids contains less than 5 % (w/w) lipid particles, less than 2.5 % lipid particles, less than 1 % lipid particles, or less than 0.5 % lipid particles.
• variant includes also variants of an apolipoprotein or an apolipoprotein mimic as reported herein wherein in the variants the amino acid sequence of the respective apolipoprotein or apolipoprotein mimic comprises one or more amino acid substitution, addition or deletion.
• the modification may increase or decrease the affinity of the apolipoprotein for an apolipoprotein receptor or an apolipoprotein converting enzyme, or may increase the stability of the apolipoprotein variant compared to the respective apolipoprotein, or may increase the solubility of the apolipoprotein variant compared to the respective apolipoprotein in aqueous solutions, or may increase the recombinant production of the apolipoprotein variant compared to the respective apolipoprotein in/by host cells.
• lipid particles and be formed directly from a solution containing a denatured protein but no detergent and no lipid by rapid dilution into a solution containing a detergent and at least one lipid but no protein.
• the generally required naturation step can be omitted, thus, providing for more simple and robust method for the production of lipid particles. Additionally a more homogeneous lipid particle is formed.
• lipid particle which comprises a protein
• ii) adding the first solution to a second solution, which comprises a lipid and a detergent but no protein, i.e. which is free of the protein, and iii) removing the detergent from the solution obtained in step ii) and thereby producing a lipid particle.
• the method for producing a lipid particle, which comprises an apolipoprotein comprises the following steps:
• a first solution comprising denatured apolipoprotein
• a second solution which comprises a lipid and a detergent but no apolipoprotein
• the second solution has a volume that is at least two-times the volume of the first solution.
• the second solution has about 3 -times to about 20-times the volume of the first solution. In one embodiment the second solution has about 5- times to about 10-times the volume of the first solution. In one embodiment the second solution comprises at least two different lipids independently of each other selected from phospholipids, fatty acids and steroid lipids. In another embodiment the at least two different lipids are two different phosphatidylcholines. In one embodiment the first phosphatidylcholine is POPC and the second phosphatidylcholine is DPPC. In one embodiment the detergent is selected from cholic acid, Zwittergent or a salt thereof.
• lipid particles from naturally occurring or recombinantly produced polypeptides such as e.g. apolipoprotein A-I or delipidated apolipoprotein A-I derived from human HDL particles.
• apolipoprotein A-I apolipoprotein A-I or delipidated apolipoprotein A-I derived from human HDL particles
• an aqueous mixture of phospholipids such as palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine with detergents such as sodium cholate are incubated with purified apolipoprotein A-I, wherein the apolipoprotein A-I is employed in native, i.e. non-denatured, form.
• the detergent is removed after the formation of the lipid particle by dialysis or diafiltration.
• the method as reported herein allows to refold and to lipidate completely denatured protein in a single step.
• a lipid particle with improved product quality can be obtained, the time consuming preconditioning of the protein can be omitted and a large scale processing for biopharmaceutical production is possible for the first time.
• the method as reported herein allows to refold and lipidate completely denatured apolipoprotein A-I in a single step.
• a lipid particle with improved product quality can be obtained, the time consuming preconditioning of the apolipoprotein A-I can be omitted and a large scale processing for biopharmaceutical production is possible for the first time.
• the main points which have to be considered for the lipid particle formation process development are i) the requirements for biological activity, and ii) technical requirements directed to the manufacturability of the lipid particle. For example, for the formation of lipid particles comprising an apolipoprotein these requirements point in opposite directions.
• saturated phospholipids containing carboxylic acid moieties with a chain of 16 carbon atoms and shorter would be chosen (e.g. dipalmitoyl-sn-glycero-3-phosphocholine, DPPC; dimyristoyl-sn-glycero-3- phosphocholine, DMPC etc.).
• non-saturated phospholipids containing carboxylic acid moieties with a chain of at least 16 carbon-atoms e.g.
• palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine, POPC; stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, SOPC) are more effective and non-liver toxic.
• an aspect is a lipid particle obtained by a method as reported herein.
• phase transition temperature of 41 °C for pure DPPC makes it easier to prepare the lipid particle compared to pure POPC that has a phase transition temperature of 4 °C.
• the obtained product is more homogeneous. This can be confirmed by lipid particle analysis via SEC -MALLS, an analytical tool which also allows the determination of the protein-lipid composition (protein-conjugate analysis).
• SEC -MALLS an analytical tool which also allows the determination of the protein-lipid composition
• Figure 2 a chromatogram of samples resolved in a size-exclusion chromatography (UV280 detection) is shown. An inhomogeniety of a sample can be seen by the occurrence of multiple separated or semi-detached peaks.
• the number of POPC molecules per apolipoprotein monomer in the lipid particle when pure POPC is used for producing the lipid particle is in one embodiment of from 40 to 85, in one embodiment of from 50 to 80, in one embodiment of from 54 to 75.
• the number of DPPC molecules per apolipoprotein monomer in the lipid particle when pure DPPC is used for producing the lipid particle is in one embodiment of from 50 to 150, in one embodiment of from 65 to 135, in one embodiment of from 76 to 123, and in one embodiment of from 86 to 102.
• the number of phospholipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 1 :3 is used for producing the lipid particle is in one embodiment of from about 50 to about 120, in one embodiment of from about 65 to about 105, and in one embodiment of from about 72 to about 96.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 1 : 1 is used for producing the lipid particle is in one embodiment of from 50 to 120, in one embodiment of from 60 to 100, in one embodiment of from 71 to 92, and in one embodiment of from 71 to 85.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 50 to 105.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 60 to 95.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 60 to 90.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 60 to 88.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 62 to 80.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 66 to 86.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment of from 64 to 70.
• the number of lipid molecules per apolipoprotein monomer in the lipid particle when a mixture of POPC and DPPC at a molar ratio of 3 : 1 is used for producing the lipid particle is in one embodiment about 66.
• a molar ratio of apolipoprotein to POPC in one embodiment of from 1 :40 to 1 : 100 is employed, in one embodiment a molar ratio of from 1 :40 to 1 :80 is employed, and in one embodiment a molar ratio of about 1 :60 is employed.
• a molar ratio of apolipoprotein to DPPC in one embodiment of from 1 :70 to 1 : 100 is employed, in one embodiment a molar ratio of from 1 :80 to 1 :90 is employed, and in one embodiment a molar ratio of about 1 : 80 is employed.
• a molar ratio of apolipoprotein to POPC and DPPC with POPC and DPPC at a 1 :3 molar ratio in one embodiment of from 1 :60 to 1 : 100 is employed, in one embodiment a molar ratio of from 1 :70 to 1 :90 is employed, and in one embodiment a molar ratio of about 1 : 80 is employed.
• a molar ratio of apolipoprotein to POPC and DPPC with POPC and DPPC at a 1 : 1 molar ratio in one embodiment of from 1 :60 to 1 : 100 is employed, in one embodiment a molar ratio of from 1 :60 to 1 :80 is employed, and in one embodiment a molar ratio of about 1 :70 is employed.
• a molar ratio of apolipoprotein to POPC and DPPC with POPC and DPPC at a 3 : 1 molar ratio in one embodiment of from 1 :60 to 1 : 100 is employed, in one embodiment a molar ratio of from 1 :50 to 1 :70 is employed, and in one embodiment a molar ratio of about 1 :60 is employed.
• the polypeptide is incubated with the detergent for about 0.5 hours to about 60 hours. In one embodiment the polypeptide is incubated with the detergent for about 0.5 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 2 hours to about 60 hours.
• the polypeptide is incubated with the detergent for about 12 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 16 hours. In one embodiment if a mixture of lipids is used for producing the lipid particle the mixture has a phase transition temperature of from 4 °C to 45 °C, in one embodiment of from 10 °C to 38 °C, and in one embodiment of from 15 °C to 35 °C.
• lipid particles comprising apolipoprotein For the formation of lipid particles comprising apolipoprotein different methods are known, such as freeze-drying, freeze-thawing, detergent solubilization followed by dialysis, microfluidization, sonification, and homogenization.
• the lipid particle may comprise as in one embodiment an average number of from 1 to 10 apolipoprotein molecules, in one embodiment of from 1 to 8 apolipoprotein molecules per lipid particle, and in one embodiment of from 1 to 4 apolipoprotein molecules per lipid particle.
• the lipid particle may comprise an average number of at least 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 apolipoprotein molecules per lipid particle. In one embodiment the average number is 1.
• the lipid particle comprises one or more further polypeptides beside the apolipoprotein.
• the lipid particle may serve as an enzymatic co-factor and/or a lipid, especially cholesterol, carrier for taking up lipids.
• One or more detergents can be present in the lipid particle as reported herein.
• a detergent can be any pharmaceutically acceptable detergent, such as a non-ionic or ionic detergent.
• the non-ionic detergent can be an alkylene oxide derivative of an organic compound which contains one or more hydroxyl groups.
• the non-ionic detergent is selected from ethoxylated and/or propoxylated alcohol or ester compounds or mixtures thereof.
• the ester is selected from esters of sorbitol and fatty acids, such as sorbitan monooleate or sorbitan monopalmitate, oily sucrose esters, polyoxyethylene sorbitane fatty acid esters, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene sterol ethers, polyoxyethylene-polypropoxy alkyl ethers, block polymers and cethyl ether, polyoxyethylene castor oil or hydrogenated castor oil derivatives and polyglycerine fatty acid esters.
• the non-ionic detergent is selected from Pluronic®, Poloxamer®, Span®, Tween®, Polysorbate®, Tyloxapol®, Emulphor® or Cremophor®.
• the ionic detergent can be a bile duct agent.
• the ionic detergent is selected from cholic acid or deoxycholic acid, or their salts and derivatives, or from free fatty acids, such as oleic acid, linoleic acid and others.
• the ionic detergent is selected from cationic lipids like Ci 0 -C 2 4 alkylamines or alkanolamine and cationic cholesterol esters.
• the detergent is a detergent with a high CMC.
• the detergent is a detergent with a CMC of at least 5 mM.
• the lipid particle comprises less than 0.75 % by weight detergent. In one embodiment the lipid particle comprises less than 0.30 % by weight detergent.
• the lipid particle comprises less than 0.1 % by weight detergent.
• the lipid particle comprises less than 0.05 % by weight detergent.
• the detergent is selected from sugar-based detergents, polyoxyalkylene-based detergents, bile-salt based detergents, synthetic detergents or a combination thereof.
• the detergent is cholic acid or Zwittergent.
• the first solution is substantially free of lipid particles.
• the method comprises after step ii) and prior to step iii) the following step iia) incubating the solution obtained in step ii).
• the polypeptide is incubated with the detergent for about 0.5 hours to about 60 hours. In one embodiment the polypeptide is incubated with the detergent for about 0.5 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 2 hours to about 60 hours. In one embodiment the polypeptide is incubated with the detergent for about 12 hours to about 20 hours. In one embodiment the polypeptide is incubated with the detergent for about 16 hours.
• the incubating and/or removing is at a temperature of from 4 °C to 45 °C.
• the removing is by diafiltration or dialysis.
• the first solution has a first volume
• the second solution has a second volume
• the protein, such as an apolipoprotein in the first solution has a defined concentration
• the lipids and the detergent in the second solution each have a defined concentration wherein in step ii) the concentration of the apolipoprotein, of the lipids and of the detergent is changed/reduced allowing the formation of a lipid particle.
• the method comprises the following step: iv) purifying the lipid particle and thereby producing a lipid particle.
• lipid particle comprising an apolipoprotein saturated phospholipids containing carboxylic acid moieties with a chain of 16 atoms and shorter would be chosen from a technical point of view (e.g. dipalmitoyl-sn-glycero-3-phosphocholine, DPPC; dimyristoyl-sn-glycero-3- phosphocholine, DMPC etc.).
• non-saturated phospholipids containing carboxylic acid moieties with a chain of at least 16 C-atoms e.g.
• palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine, POPC; stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, SOPC) are more effective and non-liver toxic.
• the phosphatidylcholines DPPC and POPC and mixtures thereof can be used for the formation of lipid particles containing an apolipoprotein.
• These exemplary phosphatidylcholines differ in one carboxylic acid moiety and have one identical carboxylic acid moiety esterified to the phosphoglycerol backbone.
• the manufacture of lipid particles was easier when DPPC was used.
• POPC was more effective in in vitro functional assays, particularly as substrate for the activation of the lecithin cholesterol acetyl transferase (LCAT) enzyme which is necessary for the conversion of the mobilized cholesterol into cholesterol ester.
• LCAT lecithin cholesterol acetyl transferase
• the lipid particle can contain only POPC.
• the number of POPC molecules per apolipoprotein monomer may vary between 54 and 75 when molar ratios from 1 :40 up to 1 :80 of apolipoprotein to lipid are used in the production of the lipid particle.
• the molar ratio of apolipoprotein to POPC is of from 1 :40 to 1 :80, in one embodiment the molar ratio is of from 1 :50 to 1 :70, in one embodiment the molar ratio is about 1 :60.
• the molar ratio of apolipoprotein to POPC is in one embodiment of from 1 :40 to 1 : 100, in one embodiment the molar ratio is of from 1 :40 to 1 :80, and in one embodiment the molar ratio is about 1 :60.
• the lipid particle can contain only DPPC.
• the number of DPPC molecules per apolipoprotein monomer may vary between 76 and 123 when molar ratios from 1 :40 up to 1 :80 of apolipoprotein to lipid are used in the production of the lipid particle.
• the molar ratio of apolipoprotein to DPPC is of from 1 :70 to 1 : 100, in one embodiment the molar ratio is of from 1 :75 to 1 :90, in one embodiment the molar ratio is about 1 :80.
• the lipid particle can be produced starting from a mixture of POPC and DPPC at a molar ratio of 1 :3.
• the number of phospholipid molecules per apolipoprotein monomer may vary between 72 and 112 when molar ratios from
• apolipoprotein to lipid up to 1 : 100 of apolipoprotein to lipid are used in the production of the lipid particle.
• the molar ratio of apolipoprotein to POPC and DPPC is of from 1 :70 to 1 :90, in one embodiment the molar ratio is of from 1 :75 to 1 :85, in one embodiment the molar ratio is about 1 :80.
• the molar ratio of apolipoprotein to POPC and DPPC with POPC and DPPC at a 1 :3 molar ratio is in one embodiment of from 1 :60 to 1 : 100, in one embodiment the molar ratio is of from 1 :70 to 1 :90, and in one embodiment the molar ratio is about 1 :80.
• the lipid particle can be produced starting from a mixture of POPC and DPPC at a molar ratio of 1 : 1.
• the number of phospholipid molecules per apolipoprotein monomer may vary between 71 and 111 when molar ratios from 1 :60 up to 1 : 100 of apolipoprotein to lipid are used in the production of the lipid particle.
• the molar ratio of apolipoprotein to POPC and DPPC is of from 1 :60 to 1 :80, in one embodiment the molar ratio is of from 1 :65 to 1 :75, in one embodiment the molar ratio is about 1.10.
• the molar ratio of apolipoprotein to POPC and DPPC with POPC and DPPC at a 1 : 1 molar ratio is in one embodiment of from 1 :60 to 1 : 100, in one embodiment the molar ratio is of from 1 :60 to 1 :80, and in one embodiment the molar ratio is about 1.10.
• the lipid particle can be produced starting from a mixture of POPC and DPPC at a molar ratio of 3 : 1.
• the number of phospholipid molecules per apolipoprotein monomer may vary between 46 and 93 when molar ratios from 1 :60 up to 1 : 100 of apolipoprotein to lipid are used in the production of the lipid particle.
• the molar ratio of apolipoprotein to POPC and DPPC is of from 1 :50 to 1 :70, in one embodiment the molar ratio is of from 1 :55 to 1 :65, in one embodiment the molar ratio is about 1 :60.
• the molar ratio of apolipoprotein to POPC and DPPC, whereby POPC and DPPC are at a 3 : 1 molar ratio is in one embodiment of from 1 :60 to 1 : 100, in one embodiment the molar ratio is of from 1 :50 to 1 :70, and in one embodiment the molar ratio is about 1 :60.
• the apolipoprotein is provided as an aqueous solution of the apolipoprotein and can be obtained from downstream processing after recombinant production or any other source of apolipoprotein production and can comprise different concentrations of apolipoprotein with varying purity.
• lipid particle formation is achieved by incubating a polypeptide with detergent solubilized lipids at their respective transition temperature. Removal of the detergent by dialysis results in the formation of lipid particles consisting of a lipid bilayer. Basically lipid particle formation can be achieved by incubating tetranectin-apolipoprotein A-I or a multimer thereof with detergent solubilized lipids at their respective transition temperature. Removal of the detergent by dialysis results in the formation of lipid particles consisting of a lipid bilayer surrounded by the oc-helical apolipoprotein.
• the lipid particle can be purified by a combination of precipitation and/or chromatography steps. For example excess detergent, i.e. detergent not part of the lipid particle, can be removed in a hydrophobic adsorption chromatography step.
• a step of the method for purifying a lipid particle comprises a hydrophobic adsorption chromatography step.
• the chromatographic material for the hydrophobic adsorption step is selected from Extracti Gel D (available from Pierce Biotechnology, Rockford IL, USA), CALBIOSORBTM (available from Calbiochem, San Diego, CA, USA), SDR 30 HyperDTM Solvent-Detergent Removal Chromatography Resin (available from PALL Corporation, Ann Arbor, MI, USA).
• Extracti Gel D available from Pierce Biotechnology, Rockford IL, USA
• CALBIOSORBTM available from Calbiochem, San Diego, CA, USA
• SDR 30 HyperDTM Solvent-Detergent Removal Chromatography Resin available from PALL Corporation, Ann Arbor, MI, USA.
• dialysis is used to remove a detergent with a high CMC.
• the lipid particle obtained by a method as reported herein can be used for the treatment and/or diagnosis of a disease or condition.
• the tetranectin-apolipoprotein A-I as reported herein or the lipid particle as reported herein can be used for the treatment and/or diagnosis of a disease or condition characterized by non-normal lipid levels or a deposition of lipid within body components, such as plaques in blood vessels.
• a disease or condition characterized by non-normal lipid levels or a deposition of lipid within body components, such as plaques in blood vessels.
• LCAT catalyzed cholesterol esterification cholesterol was incorporated in the lipid particle as reported herein by quick addition of an ethanolic cholesterol solution.
• Lipid particles containing pure POPC are better LCAT substrates than complexes containing DPPC independent of their apolipoprotein constituent, such as wild-type apolipoprotein A-I or tetranectin-apolipoprotein A-I ( Figure 3).
• Table 3 Initial velocities of cholesterol esterification in lipid particles comprising different mixtures of phospholipids.
• Macrophage like human THP1 cells obtained by exposing THP-1 monocytic leukemia cells to phorbol myristate acetate and loaded with a radioactive labeled cholesterol tracer were exposed to cholesterol acceptor test compounds.
• Efflux velocity induced by acceptor test compounds can be calculated as the ratio of cholesterol radioactivity in the supernatant to the sum of the radioactivity in the cells plus their supernatant and compared to cells exposed to medium containing no acceptors and analyzed by linear fit.
• Parallel experiments can be performed using cells exposed and not exposed to a RXR-LXR agonist which is known to upregulate mainly ABCA-1 and bias efflux toward ABCA-1 mediated transport.
• the lipid particle was applied as intravenous infusion and serial blood sampling was performed over 96 h after application. Values of liver enzymes, cholesterol, and cholesterol ester were determined. Plasma concentrations are comparable for all tested lipid particles comprising an initial distribution phase followed by log-linear decline of plasma concentrations (Figure 7). As can be seen from Table 4 pharmacokinetic parameters are similar for all tested compounds. The observed half-lives are close to 1.5 days.
• cholesterol is mobilized and esterified in plasma.
• Plasma cholesterol ester levels do continue to increase even after the concentration of tetranectin-apolipoprotein A-I is already decreasing.
• plasma tetranectin-apolipoprotein A-I levels have decreased to about 0.5 mg/ml (about 50 % of normal wild-type apolipoprotein A-I) increased cholesterol ester levels can still be detected.
• Lipid particles comprising tetranectin-apolipoprotein A-I do not induced liver enzymes in rabbits as well as in mice as can be seen from Figure 1 and 9. Also no hemolysis can be determined in plasma samples obtained two hours after intravenous application ( Figure 10). Therefore aspects of the current invention are a pharmaceutical composition and a diagnostic composition comprising a lipid particle comprising apolipoprotein as reported herein or a tetranectin-apolipoprotein A-I as reported herein.
• the lipid particle as reported herein has improved in vivo properties compared to non-lipidated apolipoprotein and other lipid particles as shown in the following Table 5.
• Table 5 In vivo properties of different apolipoproteins and lipid particles.
• the efficiency at which cholesterol is mobilized into the blood can be determined by comparing the respective excursion of total cholesterol with apolipoprotein concentrations after administration of apolipoprotein in vivo. For a quantitative assessment, the quotient of the baseline corrected area under the concentration- time curve (AUC) of total cholesterol and the area under the concentration-time curve of apolipoprotein was calculated.
• the lipid particle as reported herein especially a lipid particle comprising a tetranectin-apolipoprotein of SEQ ID NO: 01 and POPC and DPPC at a molar ratio of 3 : 1, shows enhanced cholesterol mobilization in vivo.
• Beside the lipid particle as outlined above is herein reported also a tetranectin-apolipoprotein A-I.
• Tetranectin-apolipoprotein A-I is a fusion protein of the human tetranectin trimerising structural element and the wild-type human apolipoprotein A-I.
• the amino acid sequence of the human tetranectin part can be shortened by the first 9 amino acids starting with the isoleucine residue of position 10, a naturally occurring truncation site. As a consequence of this truncation the O-glycosylation site at threonine residue of position 4 has been deleted.
• SEQ ID NO: 03 five amino acid residues "SLKGS"
• N-terminal purification tag e.g. a hexahistidine-tag, containing an IgA protease cleavage site.
• an N-terminal purification tag e.g. a hexahistidine-tag
• IgA protease cleavage site e.g. a hexahistidine-tag
• two amino acids - alanine and proline - remain at the N-terminus of the tetranectin-apolipoprotein A-I according to the current invention after purification and the tetranectin-apolipoprotein A-I has the amino acid sequence of SEQ ID NO: 01.
• the tetranectin trimerising structural element provides for a domain that allows for the formation of a trimeric tetranectin-apolipoprotein A-I multimer that is constituted by non-covalent interactions between each of the individual tetranectin- apolipoprotein A-I monomers.
• the purification-tag and the IgA protease cleavage site can be omitted resulting in a tetranectin-apolipoprotein A-I of the amino acid sequence of SEQ ID NO: 02.
• the apolipoprotein can be a variant comprising conservative amino acid substitutions or an apolipoprotein A-I mimic.
• Apolipoprotein A-I can be determined enzymatically, via NMR spectroscopy, or by using monoclonal or polyclonal anti-apolipoprotein-A-I antibodies. Other aspects as reported herein are therefore polyclonal and monoclonal antibodies specifically binding the tetranectin-apolipoprotein A-I as reported herein. Such antibodies can be obtained with methods known to a person skilled in the art. Also the labeling of the antibodies for use in immunoassays can be performed with methods known to a person of skill in the art.
• the apolipoprotein can be a variant comprising conservative amino acid substitutions, or an apolipoprotein A-I mimic.
• the tetranectin-apolipoprotein A-I has the amino acid sequence of SEQ ID NO: 02, or SEQ ID NO: 66, or SEQ ID NO: 67, wherein X is selected from SEQ ID NO: 68 to SEQ ID NO: 105.
• tetranectin-apolipoprotein A-I has the amino acid sequence of
• tetranectin-apolipoprotein A-I has the amino acid sequence of
• X can be any of the following amino acid sequences A, G, S, P, AP, GP, SP, PP, GSAP (SEQ ID NO: 68), GSGP (SEQ ID NO: 69), GSSP (SEQ ID NO: 70), GSPP (SEQ ID NO: 71), GGGS (SEQ ID NO: 72), GGGGS (SEQ ID NO: 73), GGGS GGGS (SEQ ID NO: 74), GGGGSGGGGS (SEQ ID NO: 75), GGGS GGGS GGGS (SEQ ID NO: 76), GGGGS GGGGS GGGGS (SEQ ID NO: 77), GGGSAP (SEQ ID NO: 78), GGGSGP (SEQ ID NO: 79), GGGSSP (SEQ ID NO: 80), GGGSPP (SEQ ID NO: 81), GGGGSAP (SEQ ID NO: 82), GGGGSGP (SEQ ID NO: 83), GGGGSSP (SEQ ID NO:
• SEQ ID NO: 04 Apolipoprotein A-I mimetic (1).
• SEQ ID NO: 06 Human apolipoprotein A-I.
• SEQ ID NO: 07 Human apolipoprotein A-II.
• SEQ ID NO: 08 Human apolipoprotein A-IV.
• SEQ ID NO: 09 Human apolipoprotein A-V.
• SEQ ID NO: 10 Human apolipoprotein C-I.
• SEQ ID NO: 11 Human apolipoprotein C-II.
• SEQ ID NO: 12 Human apolipoprotein C-III.
• SEQ ID NO: 13 Human apolipoprotein C-IV.
• SEQ ID NO: 14 Human apolipoprotein D.
• SEQ ID NO: 16 Human apolipoprotein F.
• SEQ ID NO: 17 Human apolipoprotein H.
• SEQ ID NO: 18 Human apolipoprotein L-I.
• SEQ ID NO: 19 Human apolipoprotein L-II.
• SEQ ID NO: 20 Human apolipoprotein L-III.
• SEQ ID NO: 21 Human apolipoprotein L-IV.
• SEQ ID NO: 22 Human apolipoprotein L-V.
• SEQ ID NO: 23 Human apolipoprotein L-VI.
• SEQ ID NO: 24 Human apolipoprotein M.
• SEQ ID NO: 25 Human apolipoprotein O.
• SEQ ID NO: 26 Human apolipoprotein OL.
• SEQ ID NO: 27 Human apolipoprotein clus.
• SEQ ID NO: 28 Apolipoprotein.
• SEQ ID NO: 29 Apolipoprotein.
• SEQ ID NO: 30 Apolipoprotein.
• SEQ ID NO: 31 Apolipoprotein.
• SEQ ID NO: 32 Apolipoprotein.
• SEQ ID NO: 33 Apolipoprotein.
• SEQ ID NO: 34 Apolipoprotein.
• SEQ ID NO: 35 Apolipoprotein.
• SEQ ID NO: 36 Apolipoprotein.
• SEQ ID NO: 37 Apolipoprotein.
• SEQ ID NO: 38 Apolipoprotein.
• SEQ ID NO: 39 Apolipoprotein.
• SEQ ID NO: 40 Apolipoprotein.
• SEQ ID NO: 41 Apolipoprotein.
• SEQ ID NO: 42 Apolipoprotein.
• SEQ ID NO: 43 Apolipoprotein.
• SEQ ID NO: 44 Apolipoprotein.
• SEQ ID NO: 45 Apolipoprotein.
• SEQ ID NO: 46 Apolipoprotein.
• SEQ ID NO: 47 Apolipoprotein.
• SEQ ID NO: 48 Apolipoprotein.
• SEQ ID NO: 49 Apolipoprotein.
• SEQ ID NO: 50 Apolipoprotein.
• SEQ ID NO: 51 Apolipoprotein.
• SEQ ID NO: 52 Apolipoprotein.
• SEQ ID NO: 53 Human tetranectin trimerization domain.
• SEQ ID NO: 54 Shortened human tetranectin trimerization domain
• SEQ ID NO: 55 Human interferon fragment.
• SEQ ID NO: 56 Hexahistidine tag.
• SEQ ID NO: 60 IgA protease cleavage site.
• SEQ ID NO: 61 IgA protease cleavage site.
• SEQ ID NO: 62 IgA protease cleavage site.
• SEQ ID NO: 64 IgA protease cleavage site.
• SEQ ID NO: 65 IgA protease cleavage site.
• SEQ ID NO: 66 Tetranectin-apolipoprotein A-I.
• SEQ ID NO: 67 Tetranectin-apolipoprotein A-I with his-tag.
• Figure 1 Results of in vivo rabbit studies conducted with five lipid particles differing in their lipid composition. Top: cholesterol mobilization and, thus, efficacy could be shown for all prepared batches. Bottom: Increase of liver enzyme was noticed for lipid particles generated by the use of DPPC as single phospholipid.
• Figure 2 SEC-MALLS analysis of lipid particles of POPC and apolipoprotein according to the current invention; molar ratios 1 :20 to 1 : 160.
• Figure 4 Initial velocity of cholesterol esterification in lipid particles containing POPC and/or DPPC.
• Figure 7 Time dependent plasma concentration of different apolipoprotein compositions.
• Figure 8 Time and concentration course of cholesterol mobilization and esterification in plasma.
• FIG. 9 Comparison of liver enzyme release by different compositions comprising apolipoprotein according to the invention in mice after a single i.v. injection of 100 mg/kg.
• Figure 10 In vivo rabbit study - spontaneous hemolysis in plasma.
• Figure 11 Analytical SEC of lipid particles using 250 mM Tris-HCl, 140 mM NaCl, pH 7.5.
• Figure 12 Analytical SEC of lipid particles using 50 mM K 2 HP0 4 , 250 mM arginine hydrochloride, 7.5 % trehalose at pH 7.5.
• Figure 13 Native PAGE of lipid particles of POPC and tetranectin- apolipoprotein A-I in molar ratios of from 1 :20 to 1 :320 (lane 1 : native Marker; lane 2: molar ratio 1 : 320; lane 3 : molar ratio 1 : 160; lane 4: molar ratio 1 : 80; lane 5 : molar ratio 1 : 80 (f/t); lane 6: molar ratio 1 : 40; lane 7: molar ratio 1 : 20; lane 8: apolipoprotein (forming hexamers)).
• Figure 14 SEC-MALLS analysis of lipid particles of POPC and tetranectin- apolipoprotein A-I in molar ratios of from 1 :20 to 1 : 160.
• Figure 15 Superposition of SEC chromatograms (UV280 signal) of lipid particle of POPC and tetranectin-apolipoprotein A-I.
• Figure 16 SEC-MALLS analysis of a lipid particle of POPC and tetranectin-apolipoprotein A-I obtained at a molar ratio of 1 AO.
• Figure 17 Native PAGE of lipid particles of DPPC and tetranectin- apolipoprotein A-I obtained with molar ratios of from 1 :20 to 1 : 100 (1 : molecular weight marker; 2: tetranectin-apolipoprotein
• A-I without lipid 3 : 1 :20; 4: 1 :40; 5 : 1 :60; 6: 1 :80; 7: 1 : 100).
• Figure 19 Native PAGE SDS of a lipid particle of tetranectin-apolipoprotein
• Lane 1 on each gel pure apolipoprotein
• lane 2 on each gel 0.1 x CMC cholate lipidated sample as references.
• Figure 22 SEC-MALLS protein conjugate analysis of lipid particle of tetranectin-apolipoprotein A-I using POPC.
• Figure 23 Results of in vivo rabbit studies performed with tetranectin-apolipoprotein A-I lipidated with DMPC (1 : 100) (di myristoyl phosphatidylcholine) (a) and not lipidated in PBS (b).
• Figure 24 SE-HPLC chromatogram of lipid particles containing wild-type apolipoprotein A-I (A) and tetranectin-apolipoprotein A-I as reported herein (B) stored at 5 °C and 40 °C.
• the chromatography was conducted with a Tosoh Haas TSK 3000 SWXL column on an ASI-100 HPLC system (Dionex, Idstein, Germany). The elution peaks were monitored at 280 nm by a UV diode array detector (Dionex). After dissolution of the concentrated samples to 1 mg/ml the column was washed with a buffer consisting of 200 mM potassium dihydrogen phosphate and 250 mM potassium chloride pH 7.0 until a stable baseline was achieved. The analyzing runs were performed under isocratic conditions using a flow rate of 0.5 ml/min. over 30 minutes at room temperature. The chromatograms were integrated manually with Chromeleon (Dionex, Idstein, Germany). Aggregation in % was determined by comparing the area under the curve (AUC) of high molecular weight forms with the AUC of the monomer peak.
• AUC area under the curve
• DLS is a non-invasive technique for measuring particle size, typically in the sub-micron size range.
• the Zetasizer Nano S apparatus (Malvern Instruments, Worcestershire, UK) with a temperature controlled quartz cuvette (25 °C) was used for monitoring a size range between 1 nm and 6 ⁇ .
• the intensity of the back scattered laser light was detected at an angle of 173°.
• the intensity fluctuates at a rate that is dependent upon the particle diffusion speed, which in turn is governed by particle size.
• Particle size data can therefore be generated from an analysis of the fluctuation in scattered light intensity (Dahneke,
• SEC -MALLS is a combination of size exclusion chromatography with a three detector system: i) UV detection, ii) refraction index detection and iii) light scattering detection.
• a Superose 6 column 10/300 GL column from GE Healthcare is used for the separation by size.
• the method is run isocratically with a PBS buffer pH 7.4 applying a flow rate of 0.4 ml/min.
• Three detector systems are connected in series.
• the complete lipid particle (protein-lipid particle) signal is monitored by the refraction index detector whereas the UV absorbance determined at 280 nm determines the signal induced by the protein part.
• the proportion of the lipid fraction is obtained by a simple subtraction of the protein UV signal from the complete signal. Applying light scattering allows for the detection of the molecular mass of the respective species and, thus, a complete and detailed description of the lipid particle.
• Detergent determination The determination of residual detergent was conducted by reversed-phase chromatography coupled with an evaporative light scattering detector (RP-ELSD). As column a Luna C18 4.6 x 150 mm, 5 ⁇ , 100 A from Phenomenex (Aillesburg, Germany) was used. After centrifugation through a 10 kDa membrane 90 ⁇ of the flow-through were used for HPLC separation. Elution was performed under isocratic conditions with 74 % (v/v) methanol solution containing
• Colum temperature was set to 30 °C.
• Detection was performed by an evaporative light scattering detector applying a nebulization temperature of 30 °C, an evaporating temperature of 80 °C and a gas flow of 1.0 1/min.
• Quantification of the residual detergent was conducted by the establishment of a calibration curve, in case of cholate in the range of 0.22 ⁇ g to 7.5 ⁇ g cholate.
• the protein concentration was determined by determining the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence.
• the tetranectin-apolipoprotein A-I fusion polypeptide was prepared by recombinant means.
• the amino acid sequence of the expressed fusion polypeptide in N- to C-terminal direction is as follows:
• VVAPPAP an IgA protease cleavage site that has the amino acid sequence of VVAPPAP (SEQ ID NO: 60), and
• the tetranectin-apolipoprotein A-I fusion polypeptides as described above are precursor polypeptides from which the tetranectin-apolipoprotein A-I fusion polypeptides was released by enzymatic cleavage in vitro using IgA protease.
• the precursor polypeptide encoding fusion gene was assembled with known recombinant methods and techniques by connection of appropriate nucleic acid segments. Nucleic acid sequences made by chemical synthesis were verified by DNA sequencing.
• the expression plasmid for the production of tetranectin-apolipoprotein A-I of SEQ ID NO: 01 encoding a fusion protein of SEQ ID NO: 31 was prepared as follows. Making of the E.coli expression plasmid
• Plasmid 4980 (4980-pBRori-URA3-LACI-SAC) is an expression plasmid for the expression of core-streptavidin in E. coli. It was generated by ligation of the 3142 bp long EcoRI/Celll-vector fragment derived from plasmid 1966 (1966-pBRori- URA3-LACI-T-repeat; reported in EP-B 1 422 237) with a 435 bp long core- streptavidin encoding EcoRI/Celll-fragment.
• the core-streptavidin E.coli expression plasmid comprises the following elements: the origin of replication from the vector pBR322 for replication in E. coli (corresponding to bp position 2517-3160 according to Sutcliffe, G., et al., Quant. Biol. 43 (1979) 77-90),
• the core-streptavidin expression cassette comprising the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard, H., et al. Methods. Enzymol. 155 (1987) 416-433 and Stueber, D., et al., Immunol. Methods IV (1990) 121-152) including a synthetic ribosomal binding site according to Stueber, D., et al. (see before), - the core-streptavidin gene,
• the final expression plasmid for the expression of the tetranectin-apolipoprotein A-I precursor polypeptide was prepared by excising the core-streptavidin structural gene from vector 4980 using the singular flanking EcoRI and Celll restriction endonuclease cleavage site and inserting the EcoRII/Celll restriction site flanked nucleic acid encoding the precursor polypeptide into the 3142 bp long
• the E.coli K12 strain CSPZ-2 (leuB, proC, trpE, th-1, ApyrF) was transformed by electroporation with the expression plasmid p(IFN-His6-IgA-tetranectin- apolipoprotein A-I).
• the transformed E.coli cells were first grown at 37 °C on agar plates. Fermentation protocol 1:
• M9 medium for pre-fermentation a M9 medium according to Sambrook et al (Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory Press; 2nd edition (December 1989) supplemented with about 1 g/1 L-leucine, about 1 g/1 L-proline and about 1 mg/1 thiamine-HCl has been used.
• 300 ml of M9-medium in a 1000 ml Erlenmeyer-flask with baffles was inoculated with 2 ml out of a primary seed bank ampoule. The cultivation was performed on a rotary shaker for 13 hours at 37 °C until an optical density (578 nm) of 1-3 was obtained.
• the feed 1 solution contained 700 g/1 glucose supplemented with 19.7 g/1 MgS0 *7 H 2 0.
• the alkaline solution for pH regulation was an aqueous 12.5 % (w/v) NH 3 solution supplemented with 50 g/1 L-leucine and 50 g/1 L-proline respectively. All components were dissolved in deionized water.
• the fermentation was carried out in a 10 1 Biostat C DCU3 ferm enter (Sartorius,
• the cytoplasmatic and soluble expressed tetranectin-apolipoprotein A-I is transferred to insoluble protein aggregates, the so called inclusion bodies, with a heat step where the whole culture broth in the fermenter is heated to 50 °C for 1 or 2 hours before harvest (see e.g. EP-B 1 486 571). Thereafter, the content of the fermenter was centrifuged with a flow-through centrifuge (13,000 rpm, 13 1/h) and the harvested biomass was stored at -20 °C until further processing.
• the synthesized tetranectin-apolipoprotein A-I precursor proteins were found exclusively in the insoluble cell debris fraction in the form of insoluble protein aggregates, so-called inclusion bodies (IBs).
• the synthesized fusion protein was found exclusively in the insoluble cell debris fraction in the form of insoluble protein aggregates, so-called inclusion bodies (IBs).
• IBs inclusion bodies
• the electrophoresis was run for 60 Minutes at 200 V and thereafter the gel was transferred the GelDOC EZ Imager (Bio-Rad) and processed for 5 minutes with UV radiation. Gel images were analyzed using Image Lab analysis software (Bio- Rad). With the three standards a linear regression curve was calculated with a coefficient of >0.99 and thereof the concentrations of target protein in the original sample was calculated.
• the feed 1 solution contained 333 g/1 yeast extract and 333 g/1 85%-glycerol supplemented with 1.67 g/1 L-methionine and 5 g/1 L-leucine and L-proline each.
• the feed 2 was a solution of 600 g/1 L-Proline.
• the alkaline solution for pH regulation was a 10 % (w/v) KOH solution and as acid a 75 % glucose solution was used. All components were dissolved in deionized water.
• the fermentation was carried out in a 10 1 Biostat C DCU3 ferm enter (Sartorius, Melsungen, Germany). Starting with 5.15 1 sterile fermentation batch medium plus 300 ml inoculum from the pre-fermentation the fed-batch fermentation was performed at 25 °C, pH 6.7 ⁇ 0.2, 300 mbar and an aeration rate of 10 1/min. Before the initially supplemented glucose was depleted the culture reached an optical density of 15 (578 nm) and the fermentation entered the fed-batch mode when feed 1 was started with 70 g/h. Monitoring the glucose concentration in the culture the feed 1 was increased to a maximum of 150 g/h while avoiding glucose accumulation and keeping the pH near the upper regulation limit of 6.9.
• feed 2 was started with a constant feed rate of 10 ml/h.
• the relative value of dissolved oxygen (p0 2 ) was kept above 50 % by increasing stirrer speed (500 rpm to 1500 rpm), aeration rate (from 10 1/min to 20
• the electrophoresis was run for 35 minutes at 200 V and then the gel was stained with Coomassie Brilliant Blue R dye, destained with heated water and transferred to an optical densitometer for digitalization (GS710, Bio-Rad). Gel images were analyzed using Quantity One 1-D analysis software (Bio-Rad). With the three standards a linear regression curve is calculated with a coefficient of >0.98 and thereof the concentrations of target protein in the original sample was calculated.
• the cytoplasmatic and soluble expressed tetranectin- apolipoprotein A-I is transferred to insoluble protein aggregates, the so called inclusion bodies (IBs), with a heat step where the whole culture broth in the fermenter is heated to 50 °C for 1 or 2 hours before harvest (see e.g. EP-B 1 486 571). After the heat step the synthesized tetranectin-apolipoprotein A-I precursor proteins were found exclusively in the insoluble cell debris fraction in the form of IBs.
• the contents of the fermenter are cooled to 4-8 °C, centrifuged with a flow-through centrifuge (13,000 rpm, 13 1/h) and the harvested biomass is stored at -20 °C until further processing.
• the total harvested biomass yield ranged between 39 g/1 and 90 g/1 dry matter depending on the expressed construct.
• Inclusion body preparation was carried out by resuspension of harvested bacteria cells in a potassium phosphate buffered solution or a Tris buffered solution (0.1 M, supplemented with 1 mM MgS0 4 , pH 6.5). After the addition of DNAse the cell were disrupted by homogenization at a pressure of 900 bar. A buffer solution comprising 1.5 M NaCl and 60 mM EDTA was added to the homogenized cell suspension. After the adjustment of the pH value to 5.0 with 25 % (w/v) HC1 the final inclusion body slurry was obtained after a further centrifugation step. The slurry was stored at -20 °C in single use, sterile plastic bags until further processing.
• the inclusion body slurry (about 15 kg) was solubilized in a guanidinium hydrochloride solution (150 1, 6.7 M). After clarification of the solubilisate by depth filtration, the solution was applied to a Zn-chelate affinity chromatography material. The fusion polypeptide was purified by Zn-chelate chromatography material and cleaved by IgA protease. Thereafter the polypeptide was further purified with an anion exchange chromatography and a cation exchange chromatography step. These steps were performed in a urea containing solution (7 M), i.e. under denaturing conditions. These steps were used for the removal of polypeptide fragments, endotoxins, and further impurities. A diafiltration into 6.7 M guanidinium hydrochloride containing solution was carried out. The obtained final solution contains denatured tetranectin-apolipoprotein A-I.
• reaction mixture was incubated overnight at 4 °C (POPC) or 41 °C (DPPC) under nitrogen atmosphere and protected from light. Finally, cholate was removed by extensive dialysis (4 °C/41 °C) against lipidation buffer. Finally samples were centrifuged to remove precipitated material.
• POPC 4 °C
• DPPC 41 °C
• Cholate solubilized lipid solutions containing pure POPC or pure DPPC have been prepared as described above.
• T m phase transition temperature.
• Lipid particle formation of tetranectin-apolipoprotein A-I was performed as described for pure lipid solutions but at the respective T m of the lipid mixture chosen.
• TIS tris-hydroxylamino methane
• Lipidation mixtures contained a defined amount of apolipoprotein each and the amount of phospholipid, e.g. POPC, was calculated accordingly. All calculations of the molar amount of lipid were based on the tetranectin-apolipoprotein A-I monomer. b) POPC and cholate
• Table 6 Lipid particle formation with tetranectin-apolipoprotein A-I as example using pure POPC. Molar ratios apolipoproteimphospholipid are calculated for the protein monomer. Controls: apolipoprotein incubated without addition of lipid (pure Apo) and lipid without apolipoprotein (no Apo).
• Lipid particle samples have been analyzed by native PAGE (see Figure 13). The most homogeneous band pattern was found with the sample 1 :80 (lane 4). In addition 1 x freeze/thaw (-80 °C) did not alter appearance of the sample (lane 5). The band patterns of samples 1 :320 and 1 : 160 indicate an inhomogeneous product resulting in multiple bands (lane 2 and 3). Samples 1 :40 and also 1 :20 have additional bands below the main product band (lane 6 and 7). The migration pattern of pure tetranectin-apolipoprotein A-I is shown in lane 8 of Figure 13.
• FIG. 14 shows the chromatogram of SEC resolved samples (UV280 detection).
• the 1 : 160 sample is divided into three separated peaks.
• the 1 :80 sample appeared to contain at least two species of different size as displayed as double peak.
• the peak obtained from sample 1 :20 shows the most homogeneous product.
• the experiment was carried out using tetranectin-apolipoprotein A-I (3.84 mg/ml; 10 mg per sample) and the molar ratio apolipoproteimphospholipid was increased from 1 :40 to 1 :80 in steps of 5. At molar ratios below 1 :40 the lipid particle formation is incomplete. Molar ratios above 1 :80 are excluded experimentally: after removal of cholate by dialysis the samples became turbid. Moreover the lipid particles became more inhomogeneous at higher lipid ratios.
• Table 7 Lipid particle formation of tetranectin-apolipoprotein A-I using pure
• Molar ratio apolipoproteimphospholipid has been calculated based on the tetranectin-apolipoprotein A-I monomer. molar ratio protein cone. protein cone. yield [%] observation apolipoprotein: before dialysis after dialysis after dialysis phospholipid [mg/ml]* [mg/ml]*
• Table 8 Summary of size exclusion chromatography results; percentages were calculated b integration of the area under the curve (AUC).
• the protein-conjugate analysis (summarized in Table 8) enables the calculation of the total molecular weight of the protein (MW protein) and the lipid component (MW lipid) for each lipid particle eluted from the SEC column. Based on the molecular weights of tetranectin-apolipoprotein A-I monomer (32.7 kDa) and POPC (760 Da) the composition of the lipid particle can be calculated (n protein and n POPC). The molecular weight of the apolipoprotein component found in the lipid particle main peak at all molar ratios was approximately 100 kDa corresponding to a tetranectin-apolipoprotein A-I trimer per lipid particle.
• the ratio n(POPC)/n(protein monomer) gives the number of POPC molecules per tetranectin-apolipoprotein A-I monomer in the lipid particle.
• the number of POPC molecules per tetranectin-apolipoprotein A-I monomer varies between 54 and 75 though molar ratios from 1 :40 up to 1 :80 have been applied.
• the value % protein is a parameter for the degree of lipidation. The lower the percentage of the protein in the lipid particle, the higher the degree of lipidation.
• Tetranectin-apolipoprotein A-I Prior to lipidation the tetranectin-apolipoprotein A-I was dialyzed against 50 mM KH 2 PO 4 , 250 mM arginine hydrochloride, 7 % trehalose, 10 mM methionine at pH 7.5. Tetranectin-apolipoprotein A-I (3.84 mg/ml, 3 mg per sample) has been lipidated using molar ratios from 1 :60 to 1 : 100 increasing lipid concentrations in steps of 5. The lipidation buffer was 250 mM Tris-HCl, 140 mM NaCl, 10 mM methionine, pH 7.5.
• Table 10 Sample overview of lipid particles of apolipoprotein with DPPC.
• Residual lipid-free apolipoprotein was found in the 1 :20 sample on native PAGE (lane 3, Figure 17).
• the 1 :40 and 1 :60 sample look most homogeneous (lanes 4 and 5) on native PAGE whereas the 1 :80 and 1 : 100 samples contain additional higher molecular bands above the main lipid particle band (lanes 6 and 7).
• SEC -MALLS protein conjugate analysis was used to characterize the composition of the lipid particles obtained after DPPC lipid particle formation (MW DPPC: 734 Da). Homogeneous SEC peaks were obtained at molar ratios of 1 :80 and below. At higher lipid ratios a pre-peak emerged (see e.g. 1 :90 sample in Table 11). Summary SEC-MALLS protein conjugate analysis of lipid particles of DPPC and tetranectin-apolipoprotein A-I.
• Protein tetranectin-apolipoprotein A-I at 3.84 mg/ml, 3 mg per sample
• Lipidation buffer 250 mM Tris-HCl, 140 mM NaCl, 10 mM methionine pH 7.5
• Lipid particle formation was straight forward and comparable to the process using pure lipids. All samples remained clear during the process and dialysis. The yield of lipid particles was similar for all ratios tested (-85 %). SEC -MALLS analysis showed that the molar ratio of 1 :80 resulted in the most homogeneous lipid particles with 90.9 % main peak, no pre-peak and 9.1 % post-peak. Protein conjugate analysis revealed the presence of one tetranectin-apolipoprotein A-I trimer per lipid particle in the main species of all samples (see Figure 18 and Tables 12 and 13).
• Table 12 Summary of SEC results; percentages were calculated by integration of the AUC.
• Protein tetranectin-lipoprotein A-I at 3.84 mg/ml, 3 mg per sample
• Lipidation buffer 250 mM Tris-HCl, 140 mM NaCl, 10 mM methionine, pH 7.5
• Protein tetranectin-apolipoprotein A-I at 3.84 mg/ml, 3 mg per sample
• Lipidation buffer 250 mM Tris-HCl, 140 mM NaCl, 10 mM methionine, pH 7.5
• the product was 90.2 % pure with respect to the main peak and contained one single tetranectin-apolipoprotein A-I trimer (see Table 17).
• Table 17 Summary protein conjugate analysis of lipid particles of 25 %
• lipid particle formation was carried out accordingly as reported in items a) to c) of this example with the following parameters and the exception that cholate was replaced by the synthetic detergent Zwittergent:
• Buffer 50 mM Tris-HCl, 7.2 M guanidinium hydrochloride,
• Lipidation buffer 250 mM Tris-HCl, 140 mM NaCl, pH 7.5
• Lipid particles comprising tetranectin-apolipoprotein A-I have been analyzed on native PAGE. Lipid-free tetranectin-apolipoprotein A-I migrates at 140 kDa (lanes 1 in Figure 19), whereas lipid particles show a characteristic shift to a higher molecular weight between 232 kDa and 440 kDa.
• the lipid particle fraction consists of two different species as displayed in two overlapping peaks in the SEC chromatogram. However, these two species are very similar, differentiating mainly in the number of tetranectin-apolipoprotein A-I molecules per particle (4.2 for peak 1 and 3.5 for peak 2).
• Table 19 Summary of protein-conjugate analysis of lipid particles formed in the presence of Zwittergent 3-8.
• the lipid particle fraction consists of two different species as displayed in two overlapping peaks in the SEC chromatogram. However, these two species are very similar, differentiating mainly in the number of tetranectin-apolipoprotein A-I molecules per particle.
• Table 21 Summary of protein-conjugate analysis of lipid particles formed in the presence of Zwittergent 3-12.
• the lipid particle fraction consists of two different species as displayed in two overlapping peaks in the SEC chromatogram. However, these two species are very similar, differentiating mainly in the number of tetranectin-apolipoprotein A-I molecules per particle.
• Table 22 Summary of protein-conjugate analysis of lipid particles formed in the presence of cholate.
• Tetranectin-apolipoprotein A-I was expressed in E. coli and purified according to Examples 1 to 3 (protocol 1). After purification, the buffer was exchanged by diafiltration to a solution containing 250 mM Tris, 140 mM NaCl, 6.7 M guanidinium hydrochloride, pH 7.4. The protein concentration was adjusted to 28 mg/ml.
• a lipid stock solution was prepared by dissolving 100 moles/1 of POPC in a buffer containing 250 mM Tris-HCl, 140 mM NaCl, 135 mM sodium cholate, pH 7.4 at room temperature. The lipid stock solution was incubated for 2 hours at room temperature. Refolding buffer was prepared by diluting 77 ml of the lipid stock mixture into 1478 ml of 250 mM Tris-HCl, 140 mM NaCl, pH 7.4. This buffer was stirred for an additional 7 hours at room temperature.
• Refolding and lipid particle formation was initiated by the addition of 162 ml tetranectin-apolipoprotein A-I in 250 mM Tris, 140 mM NaCl, 6.7 M guanidinium hydrochloride, pH 7.4 to refolding buffer. This results in a 1 : 10 dilution of the guanidinium hydrochloride. The solution was incubated at room temperature for 16 hours while constantly stirring. The removal of the detergent was carried out by diafiltration.
• Table 23 Summary protein conjugate analysis of lipid particle obtained by rapid dilution with POPC.
• Tetranectin-apolipoprotein A-I was expressed in E. coli and purified according to Examples 1 to 3 (protocol 2). After purification, the buffer was exchanged by diafiltration to a solution containing 50 mM Tris, 10 mM L-methionine, 6.7 M guanidinium hydrochloride, pH 7.4. The protein concentration was adjusted to 20.4 mg/ml.
• a lipid stock solution was prepared by dissolving 100 moles/1 of phospholipid (POPC:DPPC in a ratio 3 : 1) in a buffer containing 250 mM Tris-HCl, 140 mM NaCl, 10 mM L-methionine, 135 mM sodium cholate, pH 7.4 at room temperature.
• Refolding buffer was prepared by diluting 3.7 ml of the lipid stock solution into 35.6 ml of 250 mM Tris-HCl, 140 mM NaCl, pH 7.4. This buffer was stirred for an additional 2 hours at room temperature.
• Refolding and lipid particle formation was initiated by the addition of 9.8 ml tetranectin-apolipoprotein A-I in 50 mM Tris, 10 mM L-methionine, 6.7 M guanidinium hydrochloride, pH 8.0 to refolding buffer. This results in a 1 :5 dilution of the guanidinium hydrochloride.
• the solution was incubated at room temperature over night while constantly stirring. The removal of the detergent was carried out by diafiltration.
• Table 24 Summary protein conjugate analysis of lipid particle obtained by rapid dilution with a POPC/DPPC/cholate mixture.
• Tetranectin-apolipoprotein A-I was expressed in E. coli and purified according to Examples 1 to 3. After purification, the buffer was exchanged by diafiltration into a solution containing 250 mM Tris, 140 mM NaCl, 6.7 M guanidinium hydrochloride, pH 7.4. The protein concentration was adjusted to 30 mg/ml. Two separate lipid stock solutions were prepared. Solution A was prepared by dissolving 100 moles/1 of POPC in a buffer containing 250 mM Tris-HCl, 140 mM NaCl, 135 mM sodium cholate, pH 7.4 at room temperature.
• Solution B was prepared by dissolving 100 moles/1 of DPPC in 250 mM Tris-HCl, 140 mM NaCl, 135 mM sodium cholate, pH 7.4 at 41°C. Lipid stock solutions A and B were mixed in a ratio of 3 : 1 and incubated for 2 hours at room temperature. Refolding buffer was prepared by diluting 384 ml of the lipid stock mixture into 6365 ml of 250 mM Tris-HCl, 140 mM NaCl, pH 7.4. This buffer was stirred for an additional 24 hours at room temperature.
• Refolding and lipid particle formation was initiated by the addition of 750 ml tetranectin-apolipoprotein A-I solution in 250 mM Tris, 140 mM NaCl, 6.7 M guanidinium hydrochloride, pH 7.4 to the refolding buffer. This results in a 1 : 10 dilution of the guanidinium hydrochloride.
• the solution was incubated at room temperature for at least 12 hours while constantly stirring. Detergent removal was carried out by diafiltration.
• Tetranectin-apolipoprotein A-I was expressed in E. coli and purified over a metal chelate affinity chromatographic process from inclusion bodies (see Examples 1 to 3). After purification, the buffer was exchanged by diafiltration into a solution containing 250 mM Tris, 140 mM NaCl, 6.7 M guanidinium hydrochloride, pH 7.4. The protein concentration was adjusted to
• a lipid stock solution was prepared by dissolving 100 moles/1 of POPC in a buffer containing 250 mM Tris-HCl, 140 mM NaCl, 135 mM sodium cholate, pH 7.4 at room temperature. The lipid stock solution was incubated for 2 hours at room temperature. Refolding buffer was prepared by diluting lipid stock solution into
• Tetranectin-apolipoprotein A-I is expressed in E. coli and purified according to Examples 1 to 3. After purification, the buffer is exchanged by diafiltration to a solution containing 250 mM Tris, 140 mM NaCl, 6.7 M urea, pH 7.4. The protein concentration is adjusted to 28 mg/ml.
• a lipid stock solution is prepared by dissolving 100 moles/1 of POPC in a buffer containing 250 mM Tris-HCl, 140 mM NaCl, 135 mM sodium cholate, pH 7.4 at room temperature. The lipid stock solution is incubated for 2 hours at room temperature.
• Refolding buffer is prepared by diluting 77 ml of the lipid stock mixture into 1478 ml of 250 mM Tris-HCl, 140 mM NaCl, pH 7.4. This buffer is stirred for an additional 7 hours at room temperature.
• Refolding and lipid particle formation is initiated by the addition of 162 ml tetranectin-apolipoprotein A-I solution in 250 mM Tris, 140 mM NaCl, 6.7 M urea, pH 7.4 to refolding buffer. This results in a 1 : 10 dilution of the urea.
• the solution is incubated at room temperature for 16 hours while constantly stirring. The removal of the detergent is carried out by diafiltration.
• Example 4 The method as reported in Example 4 (first method) requires native apolipoprotein for lipid particle formation whereas the method reported in Example 5 (second method) starts with fully denatured apolipoprotein for lipid particle formation.
• the detergent was subsequently removed by diafiltration. Analysis of formed protein-lipid complexes was by SEC -MALLS. Using this method a heterogeneous product was formed wherein approximately 60 % of the formed species comprised more than three tetranectin-apolipoprotein A-I monomers.
• lipidation buffer was consisting of 6 mM cholate and 4.5 mM POPC corresponding to a lipid to protein ratio of 60: 1.
• a homogenous product was formed comprising more than 90 % of a single formed species wherein 60 molecules of lipid where bound per molecule of tetranectin-apolipoprotein A-I (see Figure 22).
• Table 28 Summary of protein conjugate analysis.
• the protein chosen for lipid particle formation is commercially available Insulin (Humalog®, Insulin Lispro, Lilly).
• Insulin Humalog®, Insulin Lispro, Lilly.
• the molecular weight of the protein is 5808 Da.
• the protein has been labeled with HS-fluorescein (6-[fluorescein-5(6)-carboxamido] hexanoic acid N-hydroxysuccinimide ester, Sigma Aldrich # 46940-5MG-F).
• Insulin-F was added to the solubilized lipid at a molar ratio proteimlipid of 1 :2 (Zwittergent 3-8) or 1 : 1.2 (Zwittergent 3-10 and cholate). The lipidation mixtures were incubated for one hour at room temperature followed by extensive dialysis against PBS pH 7.4 to remove the detergent.
• the formed lipid particles and control samples were analyzed on SE-HPLC using fluorescence detection (494 nm ext., 521 nm em.) and UV280 absorption.
• Three different samples per lipidation approach were analyzed on SE-HPLC: Insulin-F dissolved in PBS, liposomes without Insulin F in PBS and lipid particles comprising Insulin-F.
• Non-lipidated Insulin-F elutes from the column at about 40 min. elution time and the peak is detected by fluorescence and UV280 detection.
• Lipidated Insulin-F samples elute from the column as two separate peaks detected by fluorescence and UV280.
• the late peak peak maximum at approx. 40 min.
• the early peak at 15 min. elution time has a higher molecular weight then pure Insulin-F and consists of lipidated Insulin-F. Protein free lipid particles elute at 15 min. elution time
• Lipid particles comprising either palmitoyl oleoyl phosphatidylcholine (POPC) or dipalmitoyl phosphatidylcholine (DPPC) and either recombinant wild-type apolipoprotein A-I or tetranectin-apolipoprotein A-I were examined for their ability to support cholesterol esterification by LCAT.
• POPC palmitoyl oleoyl phosphatidylcholine
• DPPC dipalmitoyl phosphatidylcholine
• Tritiated cholesterol (4 %; relative to the phosphatidylcholine content on a molar basis) was incorporated in the lipid particle by addition of an ethanolic cholesterol solution.
• the capacity of the resulting protein-lipid complex to support LCAT catalyzed cholesterol esterification was tested in presence of 0.2 ⁇ g/ml recombinant LCAT enzyme (ROAR biochemical) in 125 ⁇ (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM NaN 3 ; pH 7.4; 2 mg/ml HuFAF Albumin; 4 mM Beta mercapto- ethanol) for 1 hour at 37 °C.
• ROAR biochemical recombinant LCAT enzyme
• Lipid particles were prepared using cholate as detergent by mixing recombinant wild-type apolipoprotein A-I with 3 ⁇ 4 cholesterol, a DPPC/POPC mixture, and cholate in 1 :4:80: 113 molar ratios.
• DPPC/POPC mixtures contained either 100% POPC; 75% POPC; 50% POPC; 25% POPC. After cholate removal by dialysis, the capacity of the resulting protein-lipid complex to support LCAT catalyzed cholesterol esterification was tested. 3 H cholesterol (4 %; relative to the phosphatidylcholine content on a molar basis) was incorporated in the lipid particle by addition of an ethanolic cholesterol solution.
• Macrophage like human TFIP-1 cells were obtained by exposing TFIP-1 monocytic leukemia cells to phorbol my ri state acetate. Subsequently cells were loaded by further culture in the presence of acetylated LDL containing 3 ⁇ 4 Cholesterol tracer.
• Plasma concentrations are very similar for all tested compositions showing little pronounced initial "distribution” phase followed by log-linear decline of concentrations (Figure 7, Table 3).
• PK pharmacokinetic
• HUVECs human umbilical vein endothelial cells
• Wild-type Apolipoprotein A-I containing an N-terminal histidine-tag and an IgA protease cleavage site was expressed in E. coli and purified by column chromatography as reported in the examples above. The histidine-tag was removed by IgA protease cleavage.
• Lipid particles (HDL particles) were assembled using a 1 : 150 ratio of protein to Lipoid S100 soybean phospholipid mixture. The particles were stored in a buffer containing 5 mM sodium phosphate and 1 % sucrose at pH value of 7.3. SE-HPLC revealed three distinct peaks upon incubation after lipidation and incubation for 10 days.
• HDL particles containing tetranectin-apolipoprotein A-I as reported herein which were obtained starting from a POPC:DPPC mixture (ratio POPC to DPPC of 3 : 1) were also incubated at 5 °C and 40 °C. Incubation at elevated temperature lead to a slight degree of pre-peak formation, but no significant shift to high molecular weight assemblies at 10.8 minutes ( ⁇ 2 % increase at 11 minutes). This indicates improved HDL particle stability compared to the particle containing wild-type apolipoprotein A-I.
• the efficiency at which cholesterol is mobilized into the blood can be determined by comparing the respective excursion of total cholesterol with apolipoprotein concentrations after administration of apolipoprotein in vivo.
• AUC concentration-time curve
• lipid particles (HDL particles) were assembled using a 1 : 150 ratio of protein to Lipoid S100 soybean phospholipid mixture, apolipoprotein A-I Milano variant; lipid particles (HDL particles) assembled using a 1 :40 ratio of protein to POPC, - tetranectin-apolipoprotein A-I as reported herein; lipid particles (HDL particles) were assembled using a 1 :60 ratio of protein to POPC and DPPC (POPC and DPPC at a ratio of 3 : 1).
• the three HDL particles were applied to rats.
• the values obtained for the respective AUC ratios are shown in Table 30.
• AUC time dependent concentration cholesterol in blood
• AUC time dependent apolipoprotein A-I concentration in blood

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Dispersion Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Toxicology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Marine Sciences & Fisheries (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Manufacturing Of Micro-Capsules (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (2)

Family

ID=44532851

Family Applications (1)

Country Status (9)

Cited By (4)

Families Citing this family (3)

Citations (16)

Family Cites Families (6)

• 2011
  • 2011-08-25 JP JP2013526413A patent/JP2013544488A/ja active Pending
  • 2011-08-25 CN CN2011800386711A patent/CN103068368A/zh active Pending
  • 2011-08-25 KR KR1020137005032A patent/KR20130047749A/ko not_active Application Discontinuation
  • 2011-08-25 EP EP11749404.7A patent/EP2611419A2/en not_active Withdrawn
  • 2011-08-25 CA CA2807433A patent/CA2807433A1/en not_active Abandoned
  • 2011-08-25 WO PCT/EP2011/064600 patent/WO2012028524A2/en active Application Filing
  • 2011-08-25 BR BR112013004397A patent/BR112013004397A2/pt not_active IP Right Cessation
  • 2011-08-25 RU RU2013111678/15A patent/RU2013111678A/ru not_active Application Discontinuation
  • 2011-08-25 MX MX2013001541A patent/MX2013001541A/es unknown

Patent Citations (16)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events